Connection

Robert Stuart to Treatment Outcome

This is a "connection" page, showing publications Robert Stuart has written about Treatment Outcome.
Connection Strength

0.658
  1. Safety and efficacy of oral panobinostat plus chemotherapy in patients aged 65 years or younger with high-risk acute myeloid leukemia. Leuk Res. 2019 10; 85:106197.
    View in: PubMed
    Score: 0.073
  2. Ankle Lateral Ligament Augmentation Versus the Modified Brostr?m-Gould Procedure: A 5-Year Randomized Controlled Trial. Am J Sports Med. 2019 03; 47(3):659-666.
    View in: PubMed
    Score: 0.070
  3. Sequential ofatumumab and lenalidomide for the treatment of relapsed and refractory chronic lymphocytic leukemia and small lymphocytic lymphoma. Leuk Lymphoma. 2015 Mar; 56(3):645-9.
    View in: PubMed
    Score: 0.053
  4. REVEAL-1, a phase 2 dose regimen optimization study of vosaroxin in older poor-risk patients with previously untreated acute myeloid leukaemia. Br J Haematol. 2015 Mar; 168(6):796-805.
    View in: PubMed
    Score: 0.052
  5. Primary ankle ligament augmentation versus modified Brostrom-Gould procedure: a 2-year randomized controlled trial. ANZ J Surg. 2015 Jan; 85(1-2):44-8.
    View in: PubMed
    Score: 0.052
  6. Outcomes of patients with multiple myeloma and renal impairment treated with bortezomib, cyclophosphamide, and dexamethasone without plasma exchange. Eur J Haematol. 2012 Nov; 89(5):432-4.
    View in: PubMed
    Score: 0.045
  7. Pegfilgrastim- versus filgrastim-based autologous hematopoietic stem cell mobilization in the setting of preemptive use of plerixafor: efficacy and cost analysis. Transfusion. 2012 Nov; 52(11):2375-81.
    View in: PubMed
    Score: 0.043
  8. Autologous bone marrow transplant in a patient with sickle cell disease and diffuse large B-cell lymphoma. Transplant Proc. 2003 Dec; 35(8):3089-92.
    View in: PubMed
    Score: 0.024
  9. CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial. Lancet Haematol. 2021 Jul; 8(7):e481-e491.
    View in: PubMed
    Score: 0.021
  10. A phase 2 study to assess the pharmacokinetics and pharmacodynamics of CPX-351 and its effects on cardiac repolarization in patients with acute leukemias. Cancer Chemother Pharmacol. 2019 07; 84(1):163-173.
    View in: PubMed
    Score: 0.018
  11. Pracinostat plus azacitidine in older patients with newly diagnosed acute myeloid leukemia: results of a phase 2 study. Blood Adv. 2019 02 26; 3(4):508-518.
    View in: PubMed
    Score: 0.018
  12. Malignant ovarian germ cell tumours -- a survival and prognostic analysis. Acta Oncol. 1999; 38(4):455-60.
    View in: PubMed
    Score: 0.017
  13. A Phase 1 Trial of CNDO-109-Activated Natural Killer Cells in Patients with High-Risk Acute Myeloid Leukemia. Biol Blood Marrow Transplant. 2018 08; 24(8):1581-1589.
    View in: PubMed
    Score: 0.017
  14. Reassessment of Rebleeding Risk of Forrest IB (Oozing) Peptic Ulcer Bleeding in a Large International Randomized Trial. Am J Gastroenterol. 2017 03; 112(3):441-446.
    View in: PubMed
    Score: 0.015
  15. Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study. Lancet Oncol. 2015 Sep; 16(9):1025-1036.
    View in: PubMed
    Score: 0.014
  16. Phase III open-label randomized study of cytarabine in combination with amonafide L-malate or daunorubicin as induction therapy for patients with secondary acute myeloid leukemia. J Clin Oncol. 2015 Apr 10; 33(11):1252-7.
    View in: PubMed
    Score: 0.013
  17. Dacetuzumab plus rituximab, ifosfamide, carboplatin and etoposide as salvage therapy for patients with diffuse large B-cell lymphoma relapsing after rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone: a randomized, double-blind, placebo-controlled phase 2b trial. Leuk Lymphoma. 2015; 56(9):2569-78.
    View in: PubMed
    Score: 0.013
  18. Phase I trial of bortezomib (PS-341; NSC 681239) and "nonhybrid" (bolus) infusion schedule of alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory indolent B-cell neoplasms. Clin Cancer Res. 2014 Nov 15; 20(22):5652-62.
    View in: PubMed
    Score: 0.013
  19. Hematopoietic stem-cell transplantation for advanced systemic mastocytosis. J Clin Oncol. 2014 Oct 10; 32(29):3264-74.
    View in: PubMed
    Score: 0.013
  20. Safety and tolerability of high-dose intravenous esomeprazole for prevention of peptic ulcer rebleeding. Adv Ther. 2011 Feb; 28(2):150-9.
    View in: PubMed
    Score: 0.010
  21. Southwest Oncology Group Study S0530: a phase 2 trial of clofarabine and cytarabine for relapsed or refractory acute lymphocytic leukaemia. Br J Haematol. 2010 Dec; 151(5):430-4.
    View in: PubMed
    Score: 0.010
  22. Cost effectiveness of high-dose intravenous esomeprazole for peptic ulcer bleeding. Pharmacoeconomics. 2010; 28(3):217-30.
    View in: PubMed
    Score: 0.009
  23. Single-agent laromustine, a novel alkylating agent, has significant activity in older patients with previously untreated poor-risk acute myeloid leukemia. J Clin Oncol. 2010 Feb 10; 28(5):815-21.
    View in: PubMed
    Score: 0.009
  24. Long-term survival following salvage reirradiation with concurrent chemotherapy for recurrent head and neck cancer. J S C Med Assoc. 2008 Feb; 104(2):36-9.
    View in: PubMed
    Score: 0.008
  25. Intravenous esomeprazole for prevention of peptic ulcer re-bleeding: rationale/design of Peptic Ulcer Bleed study. Aliment Pharmacol Ther. 2008 Apr; 27(8):666-77.
    View in: PubMed
    Score: 0.008
  26. High complete pathological response in locally advanced breast cancer using paclitaxel and cisplatin. Breast Cancer Res Treat. 2000 Aug; 62(3):237-44.
    View in: PubMed
    Score: 0.005
  27. Adding high-dose tamoxifen to CHOP does not influence response or survival in aggressive non-Hodgkin's lymphoma: an interim analysis of a randomized phase III trial. Med Oncol. 2000 Feb; 17(1):39-46.
    View in: PubMed
    Score: 0.005
  28. The utilization of midazolam as a pharmacologic adjunct to endotracheal intubation by paramedics. Prehosp Emerg Care. 2000 Jan-Mar; 4(1):14-8.
    View in: PubMed
    Score: 0.005
  29. Phase I and pharmacologic study of a 3-hour infusion of paclitaxel followed by cisplatinum and 5-fluorouracil in patients with advanced solid tumors. Clin Cancer Res. 1999 Jul; 5(7):1723-30.
    View in: PubMed
    Score: 0.005
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.